A Comparative effect study of transcranial magnetic stimulation and fluvoxamine in the treatment of obsessive-compulsive disorder

Effectiveness Comparison of Fluvoxamine and rTMS Treatment for OCD

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072654

Enrollment

Unknown

Registered

2023-06-20

Start date

2020-09-22

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obsessive-compulsive disorder

Interventions

rTMS group:rTMS

Fluvoxamine group:Fluvoxamine

Fluvoxamine+rTMS group:Fluvoxamine+rTMS

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Fulfilled the diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria for OCD. 2. Age 18-60 years old, gender unlimited. 3.Patients diagnosed with OCD for the first time

Exclusion criteria

Exclusion criteria: 1. Patients with epilepsy, schizophrenia, and severe depression (24 items Hamilton Depression Scale > 35 points). 2. Patients with intracranial tumors, metal, and history of brain surgery. 3. Patients with severe heart, liver and kidney diseases, and patients with a history of neurological diseases. 4. Pregnant patients.

Design outcomes

Primary

Measure	Time frame
Yale-Brown obsessive-compulsive scale;	—

Secondary

Measure	Time frame
Beck depression scale;Beck anxiety scale;	—

Countries

China

Contacts

Public ContactYanhua Qin

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

qyh19860820@126.com+86 135 8819 6674

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026